Drug Search Results
More Filters [+]

Bisoprolol

Alternative Names: bisoprolol, concor, ziac, zebeta
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Bisoprolol is used alone or in combination with other medications to treat high blood pressure. Bisoprolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve and decrease blood pressure. (Sourced from: https://medlineplus.gov/druginfo/meds/a693024.html)

Mechanisms of Action: ADRB1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bisoprolol

Countries in Clinic: China

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Hypertension

Phase 2: Cardiomyopathy, Hypertrophic

Phase 1: Angina Pectoris|Angina, Stable|Coronary Disease|Healthy Volunteers|Heart Failure, Chronic|Heart Failure, Systolic|Ventricular Dysfunction, Left

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TEMPO II

P2

Active, not recruiting

Cardiomyopathy, Hypertrophic

2025-04-11

Darmstadt-Nantong

P1

Completed

Healthy Volunteers

2023-06-18

28%

CTR20221981

P3

Not yet recruiting

Hypertension

None

CTR20231791

P1

Not yet recruiting

Hypertension

None

Recent News Events